Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real‐World Setting
In this matched-cohort real-world analysis, presence of FGFRalt had no impact on the prognosis of patients with advanced solid tumors receiving standard-of-care treatment.
Authors
- Paige Sheridan (ORCID: https://orcid.org/0000-0002-2099-6760)
- Spyros Triantos
- Martin Schüler (ORCID: https://orcid.org/0000-0002-2166-3394)
- Shibu Thomas
- Julie Paone
- Joel Greshock (ORCID: https://orcid.org/0000-0001-6567-4266)
- Kristopher Standish
- David A. Reardon (ORCID: https://orcid.org/0000-0001-6674-0157)
- Levon Demirdjian (ORCID: https://orcid.org/0000-0002-1854-3658)
- Hussein Sweiti (ORCID: https://orcid.org/0000-0002-8983-6052)
- Shubham Pant (ORCID: https://orcid.org/0000-0001-9281-480X)
- Christophe Massard (ORCID: https://orcid.org/0000-0001-5505-0564)
- Jiarui Zhang (ORCID: https://orcid.org/0000-0002-5814-2963)
- Qi Xia
- Yohann Loriot
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Aetion (United States) (US)
- Dana-Farber Cancer Institute (US)
- Janssen (United States) (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/cam4.70546
- Citations
- 1
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Janssen Research and Development